Inovio Pharmaceuticals, Inc.
INO
$1.34
$0.021.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -70.02% | -10.42% | -69.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -70.02% | -10.42% | -69.20% |
| Cost of Revenue | -22.08% | -26.29% | -28.32% | -28.95% | -18.93% |
| Gross Profit | 21.85% | 26.00% | 28.20% | 29.00% | 18.54% |
| SG&A Expenses | -8.97% | -11.03% | -11.66% | -5.35% | -6.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.47% | -21.20% | -22.85% | -21.78% | -15.02% |
| Operating Income | 17.31% | 20.99% | 22.76% | 21.80% | 14.73% |
| Income Before Tax | 23.17% | 11.97% | 20.80% | 4.24% | 27.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.17% | 11.97% | 20.80% | 4.24% | 27.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.17% | 11.97% | 20.80% | 4.24% | 27.85% |
| EBIT | 17.31% | 20.99% | 22.76% | 21.80% | 14.73% |
| EBITDA | 17.35% | 21.01% | 22.81% | 21.80% | 14.51% |
| EPS Basic | 55.96% | 47.40% | 52.23% | 41.30% | 48.01% |
| Normalized Basic EPS | 56.59% | 47.72% | 52.16% | 39.49% | 39.98% |
| EPS Diluted | 55.96% | 47.40% | 52.23% | 41.30% | 48.01% |
| Normalized Diluted EPS | 56.59% | 47.72% | 52.16% | 39.49% | 39.98% |
| Average Basic Shares Outstanding | 95.40% | 79.22% | 76.43% | 57.46% | 41.80% |
| Average Diluted Shares Outstanding | 95.40% | 79.22% | 76.43% | 57.46% | 41.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |